Advanced or metastatic cancer of the breast or colon Part 1A, 1B, and 1C: HR+/HER2- advanced or metastatic breast cancer with disease progression after at least 1 line of treatment with an endocrine therapy and cyclin-dependent kinase (CDK)4/6 inhibitor in the advanced or metastatic setting and received no more than 1 line of prior cytotoxic and/or 1 line of prior antibody-drug conjugate (ADC) therapy in the metastatic setting Part 1D: Metastatic or advanced colorectal cancer with at least having received chemotherapy and/or targeted therapy if appropriate Part 2A: HR+/HER2- advanced or metastatic breast cancer with no prior systemic therapy or chemotherapy for advanced or metastatic disease
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
You may not be if
Active or clinically significant dermatologic conditions
Active malignancy within 3 years prior to enrollment
Advanced/metastatic, symptomatic, visceral spread, that are at risk of life-threatening complications in the short term
Major surgery or radiation therapy within 3 weeks prior to study entry
Prior irradiation to \>25% of the bone marrow
Active or history of pneumonitis/interstitial lung disease requiring corticosteroids
Unmanageable ascites
Prior treatment with phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/mechanistic target of rapamycin (mTOR) pathway inhibitors may be permitted in certain study cohorts and excluded in others, as specified by the study protocol.
Renal impairment
Hepatic dysfunction
Hematologic abnormalities
Uncontrolled diabetes
Cardiac abnormalities
Active or history of clinically significant gastrointestinal (GI) or inflammatory GI disease
Other unacceptable abnormalities or prohibited therapies as defined by protocol
Clareo Health | A Study to Learn About the Study Medicine Called PF-08165784 in People With PIK3CA-Mutated Advanced or Metastatic Solid Tumors
